New scanner could replace CT for kids with cystic fibrosis
NCT ID NCT05455671
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study tested whether electrical impedance tomography (EIT), a non-invasive imaging technique, can detect lung damage in children and young adults with cystic fibrosis (CF). Researchers compared EIT results to CT scans to see if it can identify air trapping and other lung changes. The study included 48 participants aged 3-21, both healthy and with CF, to see if EIT could monitor disease progression and treatment response without radiation.
What this could mean
Our plain-language read of the trial. This is informational only โ not medical advice or a prediction.
- What this could lead to
- If successful, EIT could become a safer, radiation-free way to monitor lung health in cystic fibrosis patients, reducing the need for CT scans.
- What could go wrong
- This is a small, early-stage study (48 participants) focused on testing a device's accuracy, not a treatment. It may not prove EIT works better than current methods.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Children's Hospital Colorado
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test